Aerie Pharmaceuticals announced positive topline results for a phase 2 clinical trial of AR-1105 in macular edema associated with retinal vein occlusion, according to a press release.
The two-stage trial evaluated two formulations of the dexamethasone intravitreal implant with different steroid release profiles. In the initial safety stage, five patients received the first clinical formulation, a 340 µg dexamethasone dose in an intravitreal injection. In the second stage, 44 patients were randomly assigned to receive either the first or second formulation.
Both formulations demonstrated